Brief: Radiopharm Theranostics Receives FDA Ind Approval For Phase 2B Trial In Brain Metastases
23/07/2024 01:44
July 23 (Reuters) - Radiopharm Theranostics Ltd
RAD.AX :
* FDA IND APPROVAL FOR PHASE 2B TRIAL IN BRAIN METASTASES
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%